Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
mTOR inhibitor.
Anti-tuberculosis
TNKS1/2 inhibitor.
Inhibitor of Abl, c-Kit, and PDGFR.
SERM, androgen modulator.
Endogenous peptide hormone fragment, involved i...
DNA alkylator.
Endogenous peptide hormone, involved in cell gr...
Aminoglycoside; protein translation inhibitor, ...
Synthetic steroid hormone; ER antagonist.
Nucleoside (deoxyguanosine) analog; DNA chain t...
Immunodominant peptide fragment of PLP, used to...
Mesalazine derivative, sulfa drug; sepiapterin ...
Rapamycin analog
Indole derivative found in Isatis, Calanthe, an...
Octapeptide derived from activity-dependent neu...
Notch inhibitor.
Glucocorticoid
Bisphosphonate.
Anthracycline, DNA intercalator; topoisomerase ...